Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma. ENV515 is a novel extended-release formulation of a prostaglandin analogue formulation. It has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina.
Company Details
- Founded
- -
- Phone
- (919)973-1440
- in****@****ics.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- envisiatherapeutics.com
Envisia Therapeutics Questions
Envisia Therapeutics's helpline number is (919)973-1440
Envisia Therapeutics's website is envisiatherapeutics.com
Envisia Therapeutics's LinkedIn profile is https://www.linkedin.com/company/envisia-therapeutics
Envisia Therapeutics's industry is
Biotechnology Research
Envisia Therapeutics's top competitors are
Glaukos Corporation,
Geneone Life Science, Inc.,
Neurotech Pharmaceuticals, Inc.,
Biolabs North Carolina,
Nicox Ophthalmics Inc,
Opus Genetics,
Parion Sciences,
Sierra Nevada Research Institute,
Bluegrass Advanced Materials Llc,
Clearside Biomedical, Inc..
Envisia Therapeutics's support email address is info@envisiatherapeutics.com
Envisia Therapeutics's categories are Biotechnology Research
Envisia Therapeutics's founding year is 2013
